Candriam S.C.A. Nuvalent, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 318,367 shares of NUVL stock, worth $28.7 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
318,367
Previous 262,008
21.51%
Holding current value
$28.7 Million
Previous $19.9 Million
63.86%
% of portfolio
0.19%
Previous 0.12%
Shares
8 transactions
Others Institutions Holding NUVL
# of Institutions
207Shares Held
59.5MCall Options Held
269KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.8 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$451 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$373 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$273 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$269 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.88B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...